FDA approoves GARDASIL for boys and men 9 through 26 years of age for genital warts

Merck announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee “agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.” Peter S. Kim, Ph.D., executive vice president, and president of Merck Research Laboratories, said, “Merck has been committed to pursuing the use of GARDASIL in both males and females since the vaccine was discovered over a decade ago. We are pleased that the Advisory Committee agrees that the data support the use of GARDASIL in boys and men.”

http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20090909006540&newsLang=en

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.